Genotype in diabetes treatment and prevention

A technology of diseases and haplotypes, applied in metabolic diseases, disease diagnosis, allergic diseases, etc., can solve problems such as metabolic abnormalities

Pending Publication Date: 2020-07-03
DIAMYD MEDICAL
View PDF2 Cites 0 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

This degradation process continues for many years and eventually leads to metabolic abnormalities

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Genotype in diabetes treatment and prevention
  • Genotype in diabetes treatment and prevention
  • Genotype in diabetes treatment and prevention

Examples

Experimental program
Comparison scheme
Effect test

Embodiment 1

[0070] Example 1: Phase II of TrialNet

[0071] Three arms (A: 3 sc x 20 μg GAD-alum (n=48); B: 2 x 20 μg GAD-alum and 1 Alum (n=49); and C: 3x Alum (n=48)) randomized study, Wherrett DK et al., (Lancet, 2011 Jul 23; 378(9788):319-27) reported, at year 1, according to The 2-h AUC of C-peptide adjusted for age, sex and baseline C-peptide value was 0.412 nmol / L (0.349-0.478) in A in the GAD-alum group and 0.382 in the GAD-alum plus alum group in B nmol / L (0.322-0.446), and C was 0.413 nmol / L (0.351-0.477) in the alum group, corresponding to the mean C-peptide relative The mean losses from baseline were 44%, 42% and 41%. The authors noted that baseline and one-year C-peptide levels mirrored findings in the control groups of the other three TrialNet studies treated within 3 months of diagnosis, which also showed that alum alone was responsible for the loss of insulin secretion at 12 months No effect.

[0072] The adjusted trailing 12-month declines are thus 3.7%, 3.5% and 3.42...

Embodiment 2

[0079] Example 2: DiaPrevIt

[0080] A randomized, double-blind, placebo-controlled study (DiaPREV-IT, ClinicalTrials.gov Identifier: NCT01122446) of 50 healthy children with multiple islet autoantibodies who did not already have diabetes found that preventive treatment with GAD-alum Does not affect progression of clinical T1D onset.

[0081] The study was conducted in children aged 4-17.9 years (median age 5.2) with GADA and at least one additional islet autoantibody. Recruitment was completed in 2012 and the follow-up period was 5 years. from Eligible children of the (DiPiS) Diabetes Prediction, Environmental Determinants of Diabetes in the Young (TEDDY) study received two subcutaneous injections of 20 ug GAD-alum (n=25) or placebo (n=25) 30 days apart. The exclusion criteria were HLA DQB1*06:02 positive.

[0082] Islet cell autoantibodies predict the clinical onset of T1D, and children with more than one islet autoantibody have a 70% risk of developing T1D within 10 ye...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

PUM

No PUM Login to View More

Abstract

The present invention relates to a method for treatment or prevention of an autoimmune disease in a patient, comprising: (a) determining the HLA genotype of the patient; and (b) subjecting the patientto a treatment regimen based on said genotype.

Description

technical field [0001] The present invention relates to the technical field of drug therapy, in particular to a method for immunotherapy of a patient based on the genetic profile of the patient, and compounds and compositions used in the method. Background technique [0002] Type 1 diabetes mellitus (T1DM) is an autoimmune disease characterized by immune-mediated destruction of the insulin-secreting beta cells of the pancreas. T1DM usually has an early onset, already in childhood. [0003] Autoantibodies produced against beta cells lead to degradation of beta cells. This degradation process continues for many years and eventually leads to metabolic abnormalities. These abnormalities first manifest as impaired glucose tolerance and progress to symptomatic hyperglycemia. Antibodies identified to be associated with the development of T1DM are insulin antibody (IAA), GAD65 (GADA including truncated GADA or tGADA), IA-2 (IA-2A) and ZnT8 (ZnT8A). [0004] Administration of alu...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

Application Information

Patent Timeline
no application Login to View More
Patent Type & AuthorityApplications(China)
IPC IPC(8): A61K39/00A61K38/28A61K33/08A61P3/10A61P37/02C12Q1/6883G01N33/564
CPCA61K38/28A61K39/00A61K39/0008A61K2039/54A61K2039/55A61K2039/55505A61P3/10A61P37/02C12Q1/6883C12Q2600/156C12Q2600/172G01N33/564G01N33/56977G01N2800/042C12Q2600/106A61K9/0053A61K9/0019G01N2800/52
Inventor安德斯·埃森-默勒
OwnerDIAMYD MEDICAL